4 results about "Alpinia oxyphylla" patented technology

This invention discloses a traditional Chinese medicine formula for preventing and treating feline urinary tract diseases, its preparation method, and its application. The formula consists of the following components in parts by weight: 15-25 parts of Psoralea corylifolia, 15-25 parts of Alpinia oxyphylla, 10-20 parts of Trigonella foenum-graecum, 5-15 parts of Zea mays, 5-15 parts of Juncus effusus, 10-20 parts of Dioscorea hypoglauca, 10-20 parts of Phellodendron chinense, 10-20 parts of Lonicera japonica, 5-15 parts of Paeonia lactiflora, and 5-15 parts of Glycyrrhiza uralensis. The traditional Chinese medicine formula provided by this invention has diuretic and urinary tract mucosal repairing effects. It can effectively relieve symptoms such as urinary stones, painful urination, hematuria, or gravel in the urine caused by damp-heat in the lower abdomen. It promotes the repair of the urinary tract mucosa in animals with urinary tract diseases, alleviates inflammatory responses, and prevents the formation of crystals in the urine.

The application provides a uniform polysaccharide of Alpinia oxyphylla, a preparation method and application thereof, and belongs to the technical field of medicines. 3 The uniform polysaccharide of Alpinia oxyphylla contains galactose and glucose; the molar ratio of the galactose and the glucose is 3:22; the average molecular weight of the uniform polysaccharide of Alpinia oxyphylla is 5.26*10 3 The application also provides a preparation method of the uniform polysaccharide of Alpinia oxyphylla and application thereof in preparing immunoregulation drugs. The uniform polysaccharide of Alpinia oxyphylla obtained through the specific preparation method has good effects in regulating immunity, and provides a new choice for preparing traditional Chinese medicine innovative drugs for immune system diseases.

This invention discloses a traditional Chinese medicine composition for treating cerebrovascular diseases, belonging to the technical field of cerebrovascular disease drugs. The composition comprises the following components in parts by weight: 10-30 parts of Polygonatum sibiricum, 6-15 parts of Rosa laevigata, 6-12 parts of Euonymus alatus, 6-15 parts of Polygonum cuspidatum, 3-9 parts of Acorus tatarinowii, 3-10 parts of Alpinia oxyphylla, 3-6 parts of Aralia elata septum, 3-10 parts of Rhodiola rosea, 3-10 parts of Bletilla striata, and 1-6 parts of Cinnamomum cassia. This invention addresses the pathological characteristics of cerebrovascular diseases, including long disease courses, multiple risk factors, and involvement of multiple target organs. Through the systematic combination of ten herbs, it can simultaneously achieve cerebrovascular protection, nerve function repair, and protection against multi-organ damage. Animal experiments and clinical observations have confirmed that this composition can significantly improve patients' neurological deficit scores, reduce the incidence of complications, and has clear preventive and therapeutic effects on secondary complications such as stress ulcers and renal impairment, while also possessing antithrombotic and hemostatic properties and high safety.

This invention provides a traditional Chinese medicine composition for treating Yang deficiency constitution and its application. It comprises the following medicinal ingredients in parts by weight: 6-10 parts Eucommia ulmoides leaves, 6-10 parts Cistanche deserticola, 2-4 parts Cinnamomum cassia, 5-7 parts Alpinia galanga, 5-7 parts dried ginger, 5-7 parts Rubus idaeus, 5-7 parts Alpinia oxyphylla, 5-7 parts nutmeg, 3-5 parts walnut kernels, 3-5 parts black sesame seeds, 3-5 parts Lycium barbarum, 3-5 parts longan pulp, 3-5 parts Dioscorea opposita, 3-5 parts jujube, 2-4 parts Euryale ferox, 5-7 parts Astragalus membranaceus, 5-7 parts Codonopsis pilosula, 2-4 parts oyster shell, 5-7 parts Angelica sinensis, and 2-3 parts Saussurea involucrata culture. The preparation method of this traditional Chinese medicine composition is simple, the formulation is reasonable, and the overall effective rate in clinical trials is high.